Regenerative medicine for spinal cord injury utilizing iPS cells

Osahiko Tsuji, Satoshi Nori, Yoshiomi Kobayashi, Kanehiro Fujiyoshi, Hideyuki Okano, Yoshiaki Toyama, Masaya Nakamura

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Reports of functional recovery from spinal cord injury (SCI) after the transplantation of rat-fetus-derived neural stem/precursor cells (NS/PCs) and murine embryonic stem cells (ES cells) have raised great expectations for the successful clinical trial of stem cell transplantation therapy. However, the ethical issues concerning about destroying human embryos or fertilized oocytes to obtain such stem cells have been a major impediment to developing clinically useful stem cell sources and to use them in clinical applications. Recently, induced pluripotent stem cells (iPS cells), which can serve as a source of autologous cell transplantation, have been attracting a lot of attention as a clinically practical alternative to stem cells obtained directly from tissues. In this chapter, we outline the neural induction of murine and human iPS cells, their therapeutic efficacy in mouse and primate SCI models, and their safety in vivo.

Original languageEnglish
Title of host publicationNeuroprotection and Regeneration of the Spinal Cord
PublisherSpringer Japan
Pages229-245
Number of pages17
Volume9784431545026
ISBN (Print)9784431545026, 4431545018, 9784431545019
DOIs
Publication statusPublished - 2013 Nov 1

Fingerprint

Induced Pluripotent Stem Cells
Regenerative Medicine
Spinal Cord Injuries
Stem Cells
Neural Stem Cells
Autologous Transplantation
Cell Transplantation
Stem Cell Transplantation
Embryonic Stem Cells
Cell- and Tissue-Based Therapy
Ethics
Primates
Oocytes
Fetus
Embryonic Structures
Transplantation
Clinical Trials
Safety
Therapeutics

Keywords

  • Cell transplantation
  • Induced pluripotent stem cells
  • Neural differentiation
  • Safety
  • Spinal cord injury

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tsuji, O., Nori, S., Kobayashi, Y., Fujiyoshi, K., Okano, H., Toyama, Y., & Nakamura, M. (2013). Regenerative medicine for spinal cord injury utilizing iPS cells. In Neuroprotection and Regeneration of the Spinal Cord (Vol. 9784431545026, pp. 229-245). Springer Japan. https://doi.org/10.1007/978-4-431-54502-6_19

Regenerative medicine for spinal cord injury utilizing iPS cells. / Tsuji, Osahiko; Nori, Satoshi; Kobayashi, Yoshiomi; Fujiyoshi, Kanehiro; Okano, Hideyuki; Toyama, Yoshiaki; Nakamura, Masaya.

Neuroprotection and Regeneration of the Spinal Cord. Vol. 9784431545026 Springer Japan, 2013. p. 229-245.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tsuji, O, Nori, S, Kobayashi, Y, Fujiyoshi, K, Okano, H, Toyama, Y & Nakamura, M 2013, Regenerative medicine for spinal cord injury utilizing iPS cells. in Neuroprotection and Regeneration of the Spinal Cord. vol. 9784431545026, Springer Japan, pp. 229-245. https://doi.org/10.1007/978-4-431-54502-6_19
Tsuji O, Nori S, Kobayashi Y, Fujiyoshi K, Okano H, Toyama Y et al. Regenerative medicine for spinal cord injury utilizing iPS cells. In Neuroprotection and Regeneration of the Spinal Cord. Vol. 9784431545026. Springer Japan. 2013. p. 229-245 https://doi.org/10.1007/978-4-431-54502-6_19
Tsuji, Osahiko ; Nori, Satoshi ; Kobayashi, Yoshiomi ; Fujiyoshi, Kanehiro ; Okano, Hideyuki ; Toyama, Yoshiaki ; Nakamura, Masaya. / Regenerative medicine for spinal cord injury utilizing iPS cells. Neuroprotection and Regeneration of the Spinal Cord. Vol. 9784431545026 Springer Japan, 2013. pp. 229-245
@inbook{109f21207a284b9b9c034a2ff4e1c23a,
title = "Regenerative medicine for spinal cord injury utilizing iPS cells",
abstract = "Reports of functional recovery from spinal cord injury (SCI) after the transplantation of rat-fetus-derived neural stem/precursor cells (NS/PCs) and murine embryonic stem cells (ES cells) have raised great expectations for the successful clinical trial of stem cell transplantation therapy. However, the ethical issues concerning about destroying human embryos or fertilized oocytes to obtain such stem cells have been a major impediment to developing clinically useful stem cell sources and to use them in clinical applications. Recently, induced pluripotent stem cells (iPS cells), which can serve as a source of autologous cell transplantation, have been attracting a lot of attention as a clinically practical alternative to stem cells obtained directly from tissues. In this chapter, we outline the neural induction of murine and human iPS cells, their therapeutic efficacy in mouse and primate SCI models, and their safety in vivo.",
keywords = "Cell transplantation, Induced pluripotent stem cells, Neural differentiation, Safety, Spinal cord injury",
author = "Osahiko Tsuji and Satoshi Nori and Yoshiomi Kobayashi and Kanehiro Fujiyoshi and Hideyuki Okano and Yoshiaki Toyama and Masaya Nakamura",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/978-4-431-54502-6_19",
language = "English",
isbn = "9784431545026",
volume = "9784431545026",
pages = "229--245",
booktitle = "Neuroprotection and Regeneration of the Spinal Cord",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Regenerative medicine for spinal cord injury utilizing iPS cells

AU - Tsuji, Osahiko

AU - Nori, Satoshi

AU - Kobayashi, Yoshiomi

AU - Fujiyoshi, Kanehiro

AU - Okano, Hideyuki

AU - Toyama, Yoshiaki

AU - Nakamura, Masaya

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Reports of functional recovery from spinal cord injury (SCI) after the transplantation of rat-fetus-derived neural stem/precursor cells (NS/PCs) and murine embryonic stem cells (ES cells) have raised great expectations for the successful clinical trial of stem cell transplantation therapy. However, the ethical issues concerning about destroying human embryos or fertilized oocytes to obtain such stem cells have been a major impediment to developing clinically useful stem cell sources and to use them in clinical applications. Recently, induced pluripotent stem cells (iPS cells), which can serve as a source of autologous cell transplantation, have been attracting a lot of attention as a clinically practical alternative to stem cells obtained directly from tissues. In this chapter, we outline the neural induction of murine and human iPS cells, their therapeutic efficacy in mouse and primate SCI models, and their safety in vivo.

AB - Reports of functional recovery from spinal cord injury (SCI) after the transplantation of rat-fetus-derived neural stem/precursor cells (NS/PCs) and murine embryonic stem cells (ES cells) have raised great expectations for the successful clinical trial of stem cell transplantation therapy. However, the ethical issues concerning about destroying human embryos or fertilized oocytes to obtain such stem cells have been a major impediment to developing clinically useful stem cell sources and to use them in clinical applications. Recently, induced pluripotent stem cells (iPS cells), which can serve as a source of autologous cell transplantation, have been attracting a lot of attention as a clinically practical alternative to stem cells obtained directly from tissues. In this chapter, we outline the neural induction of murine and human iPS cells, their therapeutic efficacy in mouse and primate SCI models, and their safety in vivo.

KW - Cell transplantation

KW - Induced pluripotent stem cells

KW - Neural differentiation

KW - Safety

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84930733862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930733862&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-54502-6_19

DO - 10.1007/978-4-431-54502-6_19

M3 - Chapter

AN - SCOPUS:84930733862

SN - 9784431545026

SN - 4431545018

SN - 9784431545019

VL - 9784431545026

SP - 229

EP - 245

BT - Neuroprotection and Regeneration of the Spinal Cord

PB - Springer Japan

ER -